跳至主要内容
临床试验/CTRI/2024/04/065615
CTRI/2024/04/065615尚未招募Unknown

A Prospective, Prescription Event Monitoring (PEM) surveillance of EMROK® &/or EMROK O® in the management of Diabetic Foot Infections.

Wockhardt Ltd1 个研究点 分布在 1 个国家目标入组 7,500 人开始时间: 2024年4月23日最近更新:

试验速览

阶段
Unknown
状态
尚未招募
发起方
入组人数
7,500
试验地点
1
主要终点
1. Evaluate safety profile of EMROK in patients with DFI

研究概览

简要总结

This is a prospective and multi-centric prescription event monitoring (PEM) surveillance in patients who have been prescribed with either EMROK® or EMROK O® or both. Eligible patients will be identified by the investigator / physician based on selection criteria. All the patients must have received EMROK® or EMROK O ® in routine clinical practice at the study site. Data would be collected from the medical records of such patients prospectively.

研究设计

研究类型
Observational

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • 1.Subject any gender age 18 years or above.
  • subject must be willing to participate in the study and must provide written inform consent.

排除标准

  • subjects with history of hypersensitivity of drug or same class of drug.

结局指标

主要结局

1. Evaluate safety profile of EMROK in patients with DFI

时间窗: At day 4 and day 28 or EOT

2. Incidence of adverse events 3. Overall Global Assessment for Safety on 5 point Likert Scale

时间窗: At day 4 and day 28 or EOT

次要结局

  • 1. Clinical Success Rate at EOT(2. Clinical Responder Rate / Clinical improvement rate at EOT)

研究者

发起方
Wockhardt Ltd
申办方类型
Pharmaceutical industry-Indian
责任方
Principal Investigator
主要研究者

Dr Vishal Dalvi

Vishal Clinic

研究点 (1)

Loading locations...

相似试验